View in EDS HTML Full Text PDF Full Text

Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.

Saved in:
Bibliographic Details
Title: Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
Authors: Staubo, Sara C. (AUTHOR), Fuskevåg, Ole Martin (AUTHOR), Toft, Mathias (AUTHOR), Lie, Ingeborg H. (AUTHOR), Alvik, Kirsti M. J. (AUTHOR), Jostad, Pål (AUTHOR), Tingvoll, Stein H. (AUTHOR), Lilleng, Hallvard (AUTHOR), Rosqvist, Kristina (AUTHOR), Størset, Elisabet (AUTHOR), Odin, Per (AUTHOR), Dietrichs, Espen (AUTHOR), Dietrichs, Erik Sveberg (AUTHOR)
Source: European Journal of Neurology. Feb2024, Vol. 31 Issue 2, p1-9. 9p.
Subjects: Impulse control disorders, Parkinson's disease, Dopamine agonists, Drug monitoring, Compulsive shopping
Abstract: Background and purpose: Impulse control disorders (ICDs) are common among Parkinson's disease patients using dopamine agonists. We wanted to determine whether ICD patients have higher dopamine agonist serum concentrations than those without any sign of ICD. Methods: Patients who used either pramipexole or ropinirole depot once daily were screened for ICDs using the validated Questionnaire for Impulsive‐Compulsive Disorders in Parkinson's Disease–Rating Scale. Those who scored above the cut‐off for one or more of the four defined ICDs (gambling, compulsive sexual behavior, compulsive shopping, and binge‐eating) were compared in a case–control study to patients who scored zero points (no evidence of ICD) on the same items. They were examined clinically and evaluated using relevant scales. Three blood samples were taken on the same day: before daily dose, and then 6 and 12 h later. Results: Forty‐six patients were included: 19 ICD‐positive and 27 controls. Ropinirole serum concentrations 6 h after daily intake (Cmax) were higher in the case group compared to the control group, as was the daily ropinirole dosage. No differences were observed in serum concentrations, dosage or total drug exposure for pramipexole. Disease duration and length of dopamine agonist treatment was significantly longer among ICD patients for ropinirole, but not for pramipexole. Conclusions: The use of pramipexole may in itself confer high ICD risk, whereas ICDs among ropinirole users depend more on serum concentration and drug exposure. The pharmacokinetic properties of ropinirole make it challenging to predict its effects on patients, which supports the need for therapeutic drug monitoring to reduce risk of ICD. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 174690150
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Staubo%2C+Sara+C%2E%22">Staubo, Sara C.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fuskevåg%2C+Ole+Martin%22">Fuskevåg, Ole Martin</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Toft%2C+Mathias%22">Toft, Mathias</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lie%2C+Ingeborg+H%2E%22">Lie, Ingeborg H.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Alvik%2C+Kirsti+M%2E+J%2E%22">Alvik, Kirsti M. J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jostad%2C+Pål%22">Jostad, Pål</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tingvoll%2C+Stein+H%2E%22">Tingvoll, Stein H.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lilleng%2C+Hallvard%22">Lilleng, Hallvard</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rosqvist%2C+Kristina%22">Rosqvist, Kristina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Størset%2C+Elisabet%22">Størset, Elisabet</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Odin%2C+Per%22">Odin, Per</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dietrichs%2C+Espen%22">Dietrichs, Espen</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dietrichs%2C+Erik+Sveberg%22">Dietrichs, Erik Sveberg</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Neurology%22">European Journal of Neurology</searchLink>. Feb2024, Vol. 31 Issue 2, p1-9. 9p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Impulse+control+disorders%22">Impulse control disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Parkinson's+disease%22">Parkinson's disease</searchLink><br /><searchLink fieldCode="DE" term="%22Dopamine+agonists%22">Dopamine agonists</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+monitoring%22">Drug monitoring</searchLink><br /><searchLink fieldCode="DE" term="%22Compulsive+shopping%22">Compulsive shopping</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background and purpose: Impulse control disorders (ICDs) are common among Parkinson's disease patients using dopamine agonists. We wanted to determine whether ICD patients have higher dopamine agonist serum concentrations than those without any sign of ICD. Methods: Patients who used either pramipexole or ropinirole depot once daily were screened for ICDs using the validated Questionnaire for Impulsive‐Compulsive Disorders in Parkinson's Disease–Rating Scale. Those who scored above the cut‐off for one or more of the four defined ICDs (gambling, compulsive sexual behavior, compulsive shopping, and binge‐eating) were compared in a case–control study to patients who scored zero points (no evidence of ICD) on the same items. They were examined clinically and evaluated using relevant scales. Three blood samples were taken on the same day: before daily dose, and then 6 and 12 h later. Results: Forty‐six patients were included: 19 ICD‐positive and 27 controls. Ropinirole serum concentrations 6 h after daily intake (Cmax) were higher in the case group compared to the control group, as was the daily ropinirole dosage. No differences were observed in serum concentrations, dosage or total drug exposure for pramipexole. Disease duration and length of dopamine agonist treatment was significantly longer among ICD patients for ropinirole, but not for pramipexole. Conclusions: The use of pramipexole may in itself confer high ICD risk, whereas ICDs among ropinirole users depend more on serum concentration and drug exposure. The pharmacokinetic properties of ropinirole make it challenging to predict its effects on patients, which supports the need for therapeutic drug monitoring to reduce risk of ICD. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=174690150
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ene.16144
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 1
    Subjects:
      – SubjectFull: Impulse control disorders
        Type: general
      – SubjectFull: Parkinson's disease
        Type: general
      – SubjectFull: Dopamine agonists
        Type: general
      – SubjectFull: Drug monitoring
        Type: general
      – SubjectFull: Compulsive shopping
        Type: general
    Titles:
      – TitleFull: Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Staubo, Sara C.
      – PersonEntity:
          Name:
            NameFull: Fuskevåg, Ole Martin
      – PersonEntity:
          Name:
            NameFull: Toft, Mathias
      – PersonEntity:
          Name:
            NameFull: Lie, Ingeborg H.
      – PersonEntity:
          Name:
            NameFull: Alvik, Kirsti M. J.
      – PersonEntity:
          Name:
            NameFull: Jostad, Pål
      – PersonEntity:
          Name:
            NameFull: Tingvoll, Stein H.
      – PersonEntity:
          Name:
            NameFull: Lilleng, Hallvard
      – PersonEntity:
          Name:
            NameFull: Rosqvist, Kristina
      – PersonEntity:
          Name:
            NameFull: Størset, Elisabet
      – PersonEntity:
          Name:
            NameFull: Odin, Per
      – PersonEntity:
          Name:
            NameFull: Dietrichs, Espen
      – PersonEntity:
          Name:
            NameFull: Dietrichs, Erik Sveberg
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: Feb2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 13515101
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: European Journal of Neurology
              Type: main
ResultId 1